November 17, 2012 at 03:42 AM EST
Week in Review: PerkinElmer Buys Haoyuan Biotech, a Diagnostics Company
PerkinElmer paid $38 million to buy Shanghai Haoyuan Biotech, a company that produces four diagnostic tests for infectious diseases; Innovent Biologics, a Suzhou antibody development and manufacturing company, announced a $25 million Series B financing; Hainan Haiyao signed a LOI to acquire a 40% stake in SinoMab Bioscience Limited, an antibody company; Orchid Chemicals and Pharma of India will sell its 50% stake in a China JV to its partner for $13.9 million; Roche and Swiss Re are offering insurance for Roche’s cancer drugs to China’s middle class; Thermo Fisher Scientific opened a new $20 million manufacturing plant in Suzhou; Promega Corporation, a US-based provider of biotechnology research tools, completed a new diagnostics manufacturing facility in China; and Simcere Pharma received SFDA approval to begin China clinical trials of an anti-angiogenesis treatment for cancer. More details…. Stock Symbols: (NYSE: PKI) (SHE: 000566) (BSE: 524372) (VX: ROG) (NYSE: TMO) (NYSE: SCR) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here